Table 5.

Hazard ratios from survival analysis among patients primarily diagnosed and treated at JHH (n=394)

	HR univariate	HR adjusted	HR adjusted for Tx
≤50	0.65 (0.44–0.96)	0.64 (0.43–0.95)	0.64 (0.42–0.98)
51–55	0.85 (0.59–1.21)	0.83 (0.57–1.19)	0.75 (0.51–1.12)
56–60	1.01 (0.70–1.45)	0.99 (0.68–1.43)	0.94 (0.64–1.39)
61–65	0.81 (0.55–1.21)	0.88 (0.59–1.31)	0.89 (0.59–1.35)
≥66	Reference	Reference	Reference
Male sex	1.68 (1.22–2.31)	1.38 (0.99–1.93)	1.11 (0.79–1.56)
White race	0.79 (0.61–1.01)	0.80 (0.62–1.03)	0.97 (0.75–1.27)
Cirrhosis	1.26 (0.98–1.62)	1.26 (0.97–1.64)	1.23 (0.94–1.61)
Multiple tumors	2.19 (1.68–2.84)	1.31 (0.89–1.92)	1.25 (0.87–1.80)
Bilobar disease	2.63 (1.98–3.50)	1.41 (0.93–2.14)	0.97 (0.65–1.44)
Node positive disease	2.74 (1.93–3.90)	2.00 (1.39–2.90)	1.26 (0.84–1.88)
Size ≥5 cm	1.98 (1.54–2.54)	1.63 (1.23–2.16)	1.66 (1.23–2.23)